Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.

导出 OA

翻译打印收藏纠错

作者： Erna Milunka,Kojic ^[1] ; Minhee,Kang ^[2] ; Michelle S,Cespedes ^[3] ; Triin,Umbleja ^[2] ; Catherine,Godfrey ^[4] ; Reena T,Allen ^[5] ; Cynthia,Firnhaber ^[6] ; Beatriz,Grinsztejn ^[7] ; Joel M,Palefsky ^[8] ; Jennifer Y,Webster-Cyriaque ^[9] ; Alfred,Saah ^[10] ; Judith A,Aberg ^[3] ; Susan,Cu-Uvin ^[1]

作者单位： Department of Infectious Disease, Brown University, Providence, Rhode Island. ^[1] Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts. ^[2] Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York. ^[3] HIV Research Branch, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda. ^[4] AIDS Clinical Trials Group Network Coordinating Center, Silver Spring, Maryland. ^[5] Clinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ^[6] Infectious Diseases Department, Instituto de Pesquisa Clinica Evandro Chagas Fiocruz, Rio de Janeiro, Brazil. ^[7] Department of Medicine, University of California at San Francisco. ^[8] Oral HIV/AIDS Research Alliance (OHARA), Virology, Microbiology and Immunology, Dental Ecology, University of North Carolina, Chapel Hill. ^[9] Merck Research Labs, North Wales, Pennsylvania. ^[10]

关键词 HIV-infected women HPV vaccine anogenital disease immunogenicity vaccine safety